CN112402464A - Compound probiotic composition beneficial to type 2diabetes patients - Google Patents
Compound probiotic composition beneficial to type 2diabetes patients Download PDFInfo
- Publication number
- CN112402464A CN112402464A CN202011467658.5A CN202011467658A CN112402464A CN 112402464 A CN112402464 A CN 112402464A CN 202011467658 A CN202011467658 A CN 202011467658A CN 112402464 A CN112402464 A CN 112402464A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus
- parts
- powder
- oligosaccharide
- probiotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Botany (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a composite probiotic composition beneficial to type 2diabetes patients, which is prepared from composite probiotic powder, inulin, fructo-oligosaccharide, isomaltooligosaccharide, taro powder and xanthan gum, wherein the composite probiotic powder in the composite probiotic composition is prepared from 5 types of probiotics: lactobacillus plantarum (Lactobacillus plantarum), Lactobacillus rhamnosus (Lactobacillus rhamnosus), Lactobacillus acidophilus (Lactobacillus acidophilus), Lactobacillus casei (Lactobacillus casei), Bifidobacterium longum (Bifidobacterium longum). The probiotic composition has the effects of improving insulin sensitivity and improving glycolipid metabolism of type 2diabetes, can reduce fasting blood glucose and blood lipid levels, improve chronic low-grade inflammation, improve intestinal flora of patients, and delay occurrence and development of type 2diabetes and complications thereof, and is safe, reliable, and free of side effects.
Description
Technical Field
The invention relates to the technical field of probiotic compositions, in particular to a compound probiotic composition beneficial to type 2diabetes patients.
Background
Diabetes Mellitus (DM) is a complex disease of endocrine system metabolic disorder, the proportion of Type 2Diabetes mellitus (T2 DM) in diabetic patients exceeds 90%, the Type 2Diabetes mellitus brings serious complications and high disability and fatality rate to the patients, about 70% of the diabetic patients die of cardiovascular and cerebrovascular diseases caused by Diabetes mellitus, the serious complications cause serious reduction of the life quality of the diabetic patients, and heavy economic burden is brought to the patients, so the prevention and treatment of the Diabetes mellitus are not slow, and the DM becomes one of the most urgent public health problems in the whole world at present.
At present, oral insulin sensitizers, insulin secretagogues and alpha-glycosidase inhibitors are mainly used for clinically treating diabetes, although the blood sugar can be remarkably reduced, the medicines are easy to cause hypoglycemia after long-term use, and are easy to cause hepatotoxicity, gastrointestinal reaction and drug resistance, and the defects limit the clinical application of the existing medicines, so that the search for a novel, safe and reliable method for preventing and treating diabetes, which has no side effect, is a problem to be urgently solved.
In recent years, there is increasing evidence that the intestinal microbiota is closely related to the development and progression of diabetes. It has been found that the occurrence of T2DM is closely related to the dysbacteriosis of the intestinal tract, which may be a change in host energy absorption, metabolism, immune response and chronic inflammation due to dysbacteriosis. Probiotics play a key role in maintaining the balance of the gut flora structure.
Modern researches show that probiotic intervention based on improving intestinal flora as a target overcomes the defects of conventional medicine intervention and becomes one of effective intervention measures for preventing and treating type 2 diabetes.
However, the respective mechanisms of single probiotics are different, and the requirements of different people cannot be met, and the compound probiotic product also has various problems, such as the added probiotics have an insignificant effect, no synergistic effect among multiple probiotics, the added additives such as a sweetening agent and the like, and poor taste.
For example, application No. 201710414321X, entitled live probiotic solid beverage and its application in the treatment of type 2diabetes, discloses live probiotic solid beverage comprising lactobacillus reuteri, lactobacillus rhamnosus, bifidobacterium lactis, aloe barbadensis gel powder, resistant dextrin, galacto-oligosaccharides and adjuvants. After being taken by patients with mild and moderate type 2diabetes, the short-term index fasting blood sugar, the 2-hour postprandial blood sugar and the long-term index glycated hemoglobin are both obviously reduced, and the blood fat reducing tea has the efficacy of reducing blood fat, and can effectively reduce cholesterol, triglyceride, high-density lipoprotein and low-density lipoprotein. However, the sweetener is added, and the sweetener can influence endocrine and body metabolism and increase the risk of diabetic complications.
For example, application No. 2018111813719 entitled synbiotics compound preparation helpful for improving type 2diabetes and complications thereof and a patent application of a preparation method thereof disclose that the formulation of the synbiotics compound preparation comprises the following components: 5-10% of bifidobacterium animalis subsp lactis, 6-9% of bifidobacterium bifidum, 8-12% of lactobacillus acidophilus, 2-6% of lactobacillus reuteri, 3-8% of lactobacillus gasseri, 2-6% of inulin, 4-8% of fructo-oligosaccharide, 8-11% of xylo-oligosaccharide, 5-9% of b glucan, 8-11% of glucomannan, 2-4% of hydroxypropyl methylcellulose and 3-6% of Plantago ovata seed shell powder, and the invention also discloses a preparation method of the synbiotic compound preparation for improving type 2diabetes and complications thereof, which comprises the following steps: culturing probiotics, fermenting probiotics, freeze drying, mixing uniformly and subpackaging; the compound preparation has the function of improving biochemical indexes such as insulin resistance, blood sugar, blood fat and the like and oxidative stress, has obvious auxiliary treatment effect on the existing treatment scheme and has no obvious side effect. However, the mutual effect of probiotics is unclear, and the plantain seed is mainly responsible for diarrhea, which is not good for human health.
As described in application No. 2019103568550 entitled probiotic composition suitable for consumption by diabetic patients and its uses, probiotic compositions are provided that comprise Lactobacillus plantarum YMC 1005 (commercial number LP45), Lactobacillus acidophilus La28, Bifidobacterium lactis BAL531, and prebiotics. The prebiotics are selected from one or more of resistant starch, resistant dextrin, fructo-oligosaccharide, inulin, xylo-oligosaccharide, galacto-oligosaccharide, stachyose, beta-glucan, grape seed powder, xylan and arabinogalactan. The probiotic composition can be used as a functional food for type 2diabetes patients, can improve the blood sugar condition of the type 2diabetes patients, and is convenient to eat, safe and reliable. But only the combination of probiotics and prebiotics, no auxiliary materials for adjusting the taste and the flavor, and less probiotics and bacteria really playing a role in the intestinal tract.
Disclosure of Invention
The invention provides a compound probiotic composition beneficial to type 2diabetes patients in view of the defects. The invention aims to solve the technical problems that various probiotics are adopted, the optimal dosage and the proportion are preferred, a sweetening agent harmful to the body is not added, the dasheen powder and the xanthan gum are utilized to improve the reconstitution property and the taste of the product, the probiotic composition has the functions of improving the insulin sensitivity and the glycolipid metabolism of type 2diabetes, can reduce the fasting blood sugar and the blood fat level, improve the chronic low-grade inflammation, improve the intestinal flora of a patient, delay the occurrence and the development of type 2diabetes and complications thereof, and is safe, reliable and free of side effect.
The technical scheme of the composite probiotic composition beneficial to type 2diabetes patients is that the composite probiotic composition is prepared from composite probiotic powder, inulin, fructo-oligosaccharide, isomalto-oligosaccharide, taro powder and xanthan gum;
the composite probiotic powder in the composite probiotic composition consists of 5 types of probiotics:
lactobacillus plantarum (Lactobacillus plantarum)
Lactobacillus rhamnosus (Lactobacillus rhamnosus)
Lactobacillus acidophilus (Lactobacillus acidophilus)
Lactobacillus casei (Lactobacillus casei)
Bifidobacterium longum (Bifidobacterium longum).
The composite probiotic powder is lyophilized powder, and the viable count of each probiotic in the lyophilized powder is at least 1.0 × 1010CFU/g。
The total viable count of lactobacillus in the composite probiotic powder is at least 1.0 × 1011CFU/g。
The composite probiotic composition comprises the following components in parts by weight: 30-60 parts of inulin, 40-60 parts of fructo-oligosaccharide, 20-50 parts of isomaltooligosaccharide, 20-40 parts of taro powder and 6-10 parts of xanthan gum.
Preferably, the complex probiotic composition comprises the following components in parts by weight: 30 parts of composite probiotic powder, 45 parts of inulin, 50 parts of fructo-oligosaccharide, 37 parts of isomalto-oligosaccharide, 30 parts of taro powder and 8 parts of xanthan gum.
Preferably, the number of the live bacteria of the composite probiotic powder is 1000 hundred million/g.
The purity of inulin is more than 90 percent, the purity of fructo-oligosaccharide is more than 95 percent, the purity of isomaltooligosaccharide is more than 90 percent, and the purity of taro powder is more than 99 percent.
The invention has the beneficial effects that: the composite probiotic composition has the effects of improving insulin sensitivity and glycolipid metabolism of type 2diabetes, reducing fasting blood sugar and blood fat levels, improving chronic low-grade inflammation, improving intestinal flora of patients, and delaying the occurrence and development of type 2diabetes and complications thereof, and is safe, reliable and free of side effects.
The health-care food is prepared from raw and auxiliary materials such as lactobacillus plantarum, lactobacillus rhamnosus, lactobacillus acidophilus, lactobacillus casei and bifidobacterium longum, inulin, fructo-oligosaccharide, isomalto-oligosaccharide, taro powder and xanthan gum, and the like, and can supplement probiotics and prebiotics capable of proliferating beneficial bacteria in intestinal tracts simultaneously, so that the effect is better. It is generally believed that prebiotics provide "food" to the probiotic bacteria, which is decomposed and absorbed by the beneficial bacteria in the intestinal tract and promotes the growth and reproduction of the beneficial bacteria. The product can be compounded with prebiotics to generate a large amount of physiologically active substances, can adjust the pH value of intestinal tracts, kill pathogenic bacteria, inhibit the generation and absorption of endogenous harmful substances, and decompose and derive multiple immunologic function factors. The inulin, the fructo-oligosaccharide, the isomaltooligosaccharide and other three high-quality prebiotics are selected, can be utilized by probiotics such as lactobacillus and bifidobacterium to promote the proliferation of the prebiotics and improve the intestinal flora structure, thereby influencing the energy metabolism steady state, inhibiting pathogenic bacteria, reducing inflammation, regulating lipid metabolism, inhibiting lipid accumulation and other effects. Prebiotics affect the gut flora by increasing beneficial anaerobic bacteria in the gut and reducing the number of potentially pathogenic microorganisms. The composition containing both probiotics and prebiotics can affect the intestinal ecosystem by affecting the mucosal immune mechanism, interacting with intestinal symbiotic bacteria or potential pathogenic microorganisms, producing metabolites (such as short chain fatty acids), communicating with host cells through chemical signaling, and the like. These mechanisms of action can suppress potential pathogenic bacteria, improve the intestinal environment and enhance the intestinal barrier function.
The raw and auxiliary materials selected by the invention have the characteristics of low fat, low calorie, high fiber, promotion of intestinal flora proliferation and improvement of intestinal microecology. The composite probiotic composition has synergistic effect of different strains, and has the effects of regulating glycolipid metabolism, reducing blood sugar and blood lipid level, improving chronic low-grade inflammation and protecting pancreatic islet beta cell function.
Drawings
FIG. 1 shows the end-stage fasting blood glucose test results for the composition of the present invention;
FIG. 2 shows the results of an oral glucose tolerance (OGTT) test at the end of an 8-week test for a composition of the invention;
FIG. 3 is a graph showing area under the curve (AUC) statistics of the OGTT test time-glucose curve at the end of the 8 week test for a composition of the invention;
FIG. 4 shows the results of the experiment for improving blood lipid of type 2 diabetic rats by using the composition of the present invention;
FIG. 5 is a graph showing that the composition of the present invention improves the inflammatory status of type 2 diabetic rats;
wherein P represents P < 0.05 compared to type 2diabetes and P <0.01 compared to type 2 diabetes.
Detailed Description
For better understanding of the present invention, the technical solution of the present invention will be described in detail with specific examples, but the present invention is not limited thereto.
The raw materials of the invention are as follows:
lactobacillus plantarum (Lactobacillus plantarum) LP-ONLLY (China center for culture Collection of microorganisms CGMCC 1258).
Lactobacillus rhamnosus LR22 (center for preservation of microorganisms and germs, Pasteur, France CNCM I-4474);
lactobacillus acidophilus (Lactobacillus acidophilus) LAll-Onlly (China center for culture Collection of microorganisms CGMCC 2106);
lactobacillus casei (Lactobacillus casei) LC18 (center for conservation of microorganisms and moraxella, France CNCM I-4458);
bifidobacterium longum (Bifidobacterium longum) BL88-ONLLY (China center for culture Collection of microorganisms CGMCC 2107);
inulin (content > 90%);
fructooligosaccharides (content > 95%);
isomaltooligosaccharide (> 90%);
taro powder (content > 99%).
Example 1
A composite probiotic composition beneficial to type 2diabetes patients comprises the following components in parts by weight: 30 parts of composite probiotic powder, 45 parts of inulin, 50 parts of fructo-oligosaccharide, 37 parts of isomalto-oligosaccharide, 30 parts of taro powder and 8 parts of xanthan gum; wherein the viable count of the composite probiotic powder is 1000 hundred million/g, the inulin purity is more than 90 percent, the fructo-oligosaccharide purity is more than 95 percent, the isomalto-oligosaccharide purity is more than 90 percent, and the taro powder purity is more than 99 percent.
The composite probiotic powder in the composite probiotic composition consists of 5 types of probiotics:
lactobacillus plantarum (Lactobacillus plantarum)
Lactobacillus rhamnosus (Lactobacillus rhamnosus)
Lactobacillus acidophilus (Lactobacillus acidophilus)
Lactobacillus casei (Lactobacillus casei)
Bifidobacterium longum (Bifidobacterium longum).
The composite probiotic powder is lyophilized powder, and the viable count of each probiotic in the lyophilized powder is at least 1.0 × 1010CFU/g。
Example 2
A composite probiotic composition beneficial to type 2diabetes patients comprises the following components in parts by weight: 50 parts of composite probiotic powder, 40 parts of inulin, 42 parts of fructo-oligosaccharide, 35 parts of isomalto-oligosaccharide, 25 parts of taro powder and 8 parts of xanthan gum; wherein the viable count of the composite probiotic powder is 1000 hundred million/g, the inulin purity is more than 90 percent, the fructo-oligosaccharide purity is more than 95 percent, the isomalto-oligosaccharide purity is more than 90 percent, and the taro powder purity is more than 99 percent.
The composite probiotic powder in the composite probiotic composition consists of 5 types of probiotics:
lactobacillus plantarum (Lactobacillus plantarum)
Lactobacillus rhamnosus (Lactobacillus rhamnosus)
Lactobacillus acidophilus (Lactobacillus acidophilus)
Lactobacillus casei (Lactobacillus casei)
Bifidobacterium longum (Bifidobacterium longum).
The composite probiotic powder is lyophilized powder, and the viable count of each probiotic in the lyophilized powder is at least 1.0 × 1010CFU/g。
Example 3
A composite probiotic composition beneficial to type 2diabetes patients comprises the following components in parts by weight: 40 parts of composite probiotic powder, 40 parts of inulin, 45 parts of fructo-oligosaccharide, 37 parts of isomalto-oligosaccharide, 30 parts of taro powder and 8 parts of xanthan gum; wherein the viable count of the composite probiotic powder is 1000 hundred million/g, the inulin purity is more than 90 percent, the fructo-oligosaccharide purity is more than 95 percent, the isomalto-oligosaccharide purity is more than 90 percent, and the taro powder purity is more than 99 percent.
The composite probiotic powder in the composite probiotic composition consists of 5 types of probiotics:
lactobacillus plantarum (Lactobacillus plantarum)
Lactobacillus rhamnosus (Lactobacillus rhamnosus)
Lactobacillus acidophilus (Lactobacillus acidophilus)
Lactobacillus casei (Lactobacillus casei)
Bifidobacterium longum (Bifidobacterium longum).
The composite probiotic powder is lyophilized powder, and the viable count of each probiotic in the lyophilized powder is at least 1.0 × 1010CFU/g。
Comparative example 1
This comparative example differs from example 1 in that the composite probiotic powder in the composite probiotic composition consists of 4 probiotics:
lactobacillus plantarum (Lactobacillus plantarum)
Lactobacillus rhamnosus (Lactobacillus rhamnosus)
Lactobacillus acidophilus (Lactobacillus acidophilus)
Lactobacillus casei (Lactobacillus casei)
The composite probiotic powder is lyophilized powder, and the viable count of each probiotic in the lyophilized powder is at least 1.0 × 1010CFU/g。
Comparative example 2
This comparative example differs from example 1 in that the composite probiotic powder in the composite probiotic composition consists of 4 probiotics:
lactobacillus plantarum (Lactobacillus plantarum)
Lactobacillus rhamnosus (Lactobacillus rhamnosus)
Lactobacillus acidophilus (Lactobacillus acidophilus)
Bifidobacterium longum (Bifidobacterium longum).
The composite probiotic powder is lyophilized powder, and the viable count of each probiotic in the lyophilized powder is at least 1.0 × 1010CFU/g。
Test example 1
Effect of the products of inventive example 1 and comparative examples 1-2 on type 2 diabetic SD rats
50 SPF SD rats (male, 6-week old) are taken, 8 of the SD rats are fed with common feed (H10010, Beijing Huafukang Biotechnology GmbH), 42 of the SD rats are fed with high-fat feed (H10060, Beijing Huafukang Biotechnology GmbH), after 8 weeks of feeding, a high-fat feed feeding group is injected with 2% STZ solution in an abdominal cavity according to a dose of 25 mg/kg-bw for molding, after 72 hours of molding, the SD rats are subjected to fasting glucose monitoring, every other day retest, and after 3 times of blood glucose detection, the molding is successful by taking fasting glucose all larger than 11.1 mmol/L.
The rats with type 2diabetes mellitus successfully modeled were excluded from those with higher and lower fasting blood glucose, and 32 rats with type 2diabetes mellitus with relatively stable blood glucose level were selected and randomly divided into 4 groups (8 rats per group), type 2diabetes mellitus control group, example 1 group, comparative example 1 group and comparative example 2 group. The groups of example 1, comparative example 1 and comparative example 2 were gavaged at a dose of 12.6mg/kg · bw, and the normal control group and the type 2 diabetic group were given the same volume of distilled water once a day for continuous intervention for 8 weeks, and were fasted for 14h at the end of the 7 th week of gavage for the OGTT test, rats of each group were sacrificed at the end of the 8 th week, fasting blood glucose levels were measured after fasting for 14h from the night of the first 1 day, and blood samples were left to test for TG, TC, HDL-C, LDL-C, IL-6, IL-1 β, TNF- α, and the like, respectively.
1. The products of the invention in the example 1 and the comparative examples 1-2 have the effect of improving the blood sugar of SD rats with type 2diabetes
The improvement effect of the products of example 1 and comparative examples 1-2 on fasting plasma glucose of type 2 diabetic SD rats is shown in table 1:
TABLE 1
P <0.01 compared to type 2diabetes group.
As can be seen from the attached figure 1 of the specification, at the 8 th week of intervention, compared with the type 2diabetes group, the fasting plasma glucose of the rats of the example group is obviously reduced (p <0.01), and the fasting plasma glucose of the rats of the comparative example 1 and the rats of the comparative example 2 is reduced to different degrees but has no obvious difference, which indicates that the probiotic product of the example group can improve the fasting plasma glucose of the type 2diabetes rats, and the effect is better than that of the products of the comparative example 1 and the comparative example 2.
As can be seen from the attached figure 2 in the specification, after 8 weeks of probiotic intervention, the rats with type 2diabetes can obviously reduce the peak value of fasting blood glucose and the postprandial blood glucose of 2 h. As can be seen from the drawings attached to the specification and fig. 3, the area under the glucose tolerance curve of the example group is significantly lower than that of the type 2diabetes group (p <0.01) compared to the model group.
The results show that the probiotic intervention in the example group can obviously reduce the fasting blood sugar and the peak value of the blood sugar of the diabetic rat, stabilize the blood sugar and improve the glucose tolerance state, has a certain blood sugar regulating function for the type 2 diabetic rat, and has better effect than the comparative example 1 and the comparative example 2.
2. The products of the invention in the example 1 and the comparative examples 1-2 have the effect of improving the blood fat of SD rats with type 2diabetes
As can be seen from FIG. 4 in the drawings attached to the specification, the TG levels (P < 0.05) of type 2 diabetic rats were significantly improved in the example group, and although TC and LDL-C levels were also reduced, there was no significant difference, and HDL-C levels were increased but there was no significant difference. The results show that the example group has the effect of reducing the blood lipid level of the type 2 diabetic rats, and the effect is better than that of the comparative example 1 and the comparative example 2.
3. The products of example 1 and comparative examples 1-2 of the invention have the effect of improving chronic low-grade inflammation of SD rats with type 2diabetes
The results of the measurement of inflammatory factors in rats in each group after 8 weeks of intervention are shown in figure 5 of the accompanying drawings. The differences in serum TNF-alpha levels in the example group compared to the type 2diabetes model group were statistically significant (P <0.01), and the differences in serum IL-6 and IL-1 beta levels in the example group compared to the type 2diabetes model group were both statistically significant (P < 0.05). It is demonstrated that probiotic intervention in the example group has an effect of improving the chronic low-grade inflammatory state of type 2 diabetic rats, whereas TNF-alpha, IL-6 and IL-1 beta levels in the comparative example 1 and comparative example 2 groups have a different degree of improvement compared to the type 2 diabetic group, but have no significant difference.
Claims (6)
1. The compound probiotic composition beneficial to type 2diabetes patients is characterized by being prepared from compound probiotic powder, inulin, fructo-oligosaccharide, isomalto-oligosaccharide, taro powder and xanthan gum;
the composite probiotic powder in the composite probiotic composition consists of 5 types of probiotics:
lactobacillus plantarum (Lactobacillus plantarum)
Lactobacillus rhamnosus (Lactobacillus rhamnosus)
Lactobacillus acidophilus (Lactobacillus acidophilus)
Lactobacillus casei (Lactobacillus casei)
Bifidobacterium longum (Bifidobacterium longum).
2. The composition of claim 1, for the benefit of type 2diabetesThe probiotic composition is characterized in that the composite probiotic powder is freeze-dried powder, and the viable count of each probiotic in the freeze-dried powder is at least 1.0 x 1010CFU/g。
3. The composite probiotic composition for the patients with type 2diabetes according to claim 2, wherein the total viable count of lactic acid bacteria in the composite probiotic powder is at least 1.0 x 1011CFU/g。
4. The complex probiotic composition beneficial to type 2diabetes patients according to claim 1, characterized in that the complex probiotic composition comprises, in parts by weight: 30-60 parts of inulin, 40-60 parts of fructo-oligosaccharide, 20-50 parts of isomaltooligosaccharide, 20-40 parts of taro powder and 6-10 parts of xanthan gum.
5. The complex probiotic composition beneficial to type 2diabetes patients according to claim 1, characterized by comprising the following ingredients in parts by weight: 30 parts of composite probiotic powder, 45 parts of inulin, 50 parts of fructo-oligosaccharide, 37 parts of isomalto-oligosaccharide, 30 parts of taro powder and 8 parts of xanthan gum.
6. The composite probiotic composition beneficial to type 2diabetes patients according to claim 4, characterized in that inulin purity is > 90%, fructo-oligosaccharide purity is > 95%, isomalto-oligosaccharide purity is > 90%, and taro powder purity is > 99%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011467658.5A CN112402464B (en) | 2020-12-14 | 2020-12-14 | Compound probiotic composition beneficial to type 2diabetes patients |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011467658.5A CN112402464B (en) | 2020-12-14 | 2020-12-14 | Compound probiotic composition beneficial to type 2diabetes patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112402464A true CN112402464A (en) | 2021-02-26 |
| CN112402464B CN112402464B (en) | 2023-02-07 |
Family
ID=74775769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011467658.5A Active CN112402464B (en) | 2020-12-14 | 2020-12-14 | Compound probiotic composition beneficial to type 2diabetes patients |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112402464B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113274481A (en) * | 2021-05-28 | 2021-08-20 | 湖北明德医疗科技有限责任公司 | Composition for regulating blood sugar and preparation method and application thereof |
| CN113712992A (en) * | 2021-09-02 | 2021-11-30 | 武汉英纽林生物科技有限公司 | Application of inulin-containing prebiotics and hydrogen-rich water in preparation of blood sugar control medicine |
| CN115804454A (en) * | 2021-09-14 | 2023-03-17 | 武汉蜜欢健康产业发展有限公司 | Probiotic composition, nutritional composition and application thereof |
| CN115948273A (en) * | 2022-06-21 | 2023-04-11 | 合肥瀚微生物科技有限公司 | Bifidobacterium bifidum for treating diabetes and related disorders |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106174585A (en) * | 2016-06-30 | 2016-12-07 | 山东凤凰生物有限公司 | Hypoglycemic compositions and hypoglycemic compound probiotic spy's dietary seafood |
| CN108157973A (en) * | 2017-12-14 | 2018-06-15 | 上海交通大学医学院附属瑞金医院 | The probiotic composition and its preparation of a kind of beneficial glycolipid metabolism function and application |
| CN110638842A (en) * | 2018-06-26 | 2020-01-03 | 上海立龙生物科技有限公司 | Probiotics composition for improving hyperglycemia |
-
2020
- 2020-12-14 CN CN202011467658.5A patent/CN112402464B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106174585A (en) * | 2016-06-30 | 2016-12-07 | 山东凤凰生物有限公司 | Hypoglycemic compositions and hypoglycemic compound probiotic spy's dietary seafood |
| CN108157973A (en) * | 2017-12-14 | 2018-06-15 | 上海交通大学医学院附属瑞金医院 | The probiotic composition and its preparation of a kind of beneficial glycolipid metabolism function and application |
| CN110638842A (en) * | 2018-06-26 | 2020-01-03 | 上海立龙生物科技有限公司 | Probiotics composition for improving hyperglycemia |
Non-Patent Citations (2)
| Title |
|---|
| 白璐等: "益生菌对2型糖尿病小鼠的调节作用", 《食品工业科技》 * |
| 赵丹等: "长双歧杆菌DD98对2型糖尿病及肥胖小鼠的改善作用", 《现代食品科技》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113274481A (en) * | 2021-05-28 | 2021-08-20 | 湖北明德医疗科技有限责任公司 | Composition for regulating blood sugar and preparation method and application thereof |
| CN113712992A (en) * | 2021-09-02 | 2021-11-30 | 武汉英纽林生物科技有限公司 | Application of inulin-containing prebiotics and hydrogen-rich water in preparation of blood sugar control medicine |
| CN115804454A (en) * | 2021-09-14 | 2023-03-17 | 武汉蜜欢健康产业发展有限公司 | Probiotic composition, nutritional composition and application thereof |
| CN115948273A (en) * | 2022-06-21 | 2023-04-11 | 合肥瀚微生物科技有限公司 | Bifidobacterium bifidum for treating diabetes and related disorders |
| CN115948273B (en) * | 2022-06-21 | 2023-07-18 | 合肥瀚微生物科技有限公司 | Bifidobacterium bifidum for treating diabetes and related diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112402464B (en) | 2023-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112402464B (en) | Compound probiotic composition beneficial to type 2diabetes patients | |
| CN111671791A (en) | Micro-ecological composition for improving constipation by targeting intestinal flora and preparation thereof | |
| EP2269465A1 (en) | Compositions comprising Bifidobacterium adolescentis | |
| CN106994134B (en) | Application of intestinal probiotics in prevention and/or treatment of diabetes and related diseases thereof | |
| KR20190068078A (en) | Lactobacillus paracasei AO356 strain with Anti-Obesity Ability and Composition for treatment or improvement or preventing of obesity comprising the same | |
| CN109419816B (en) | Application of bacteroides cellulolyticus in preventing and/or treating heart diseases | |
| US20130309212A1 (en) | Lactobacillus salivarius and method for preparing metabolite thereof, composition of lactobacillus salivarius and metabolite thereof and use of the composition | |
| CN112970990A (en) | Probiotic solid beverage with weight-losing and lipid-lowering effects and preparation process thereof | |
| KR100943747B1 (en) | Composition for Prevention and Treatment of Diabetes Mellitus with Lactobacillus gasseri BNR17 | |
| CN112274577B (en) | Use of a composition comprising a fermentation of a Musa species and a probiotic composition | |
| KR102548488B1 (en) | A Novel Lactobacillus reuteri strain derived from Panax ginseng and the use thereof | |
| KR20040037011A (en) | Food Composition Containing a Lactic Acid Bacteria | |
| CN110638842A (en) | Probiotics composition for improving hyperglycemia | |
| CN113575973A (en) | Composition for protecting liver of diabetic and preparation method thereof | |
| CN110869035A (en) | Application of xenobacter saxifragi in preparation of composition for preventing and/or treating lipid metabolism-related diseases | |
| KR102158598B1 (en) | Composition for preventing or treating behcet's diseases or herpes simplex virus infection containing lactobacillus animalis | |
| KR102083470B1 (en) | COMPOSITION FOR IMPROVING INTESTINAL MICROFLORA AND PREVENTING, TREATING OBESITY COMPRISING POLYSACCHARIDES FROM FERMENTED Aureobasidium pullulans AS AN EFFECTIVE INGREDIENT | |
| KR102077720B1 (en) | Pediococcus acidilactici AO22 strain with Anti-Obesity Ability and Composition for treatment or improvement or preventing of obesity comprising the same | |
| KR102501958B1 (en) | A novel Lactobacillus fermentum strain derived from Panax ginsengand the use thereof | |
| CN106974940B (en) | Application of probiotics of scleritis in treating and preventing obesity and related diseases | |
| TWI817342B (en) | Prebiotic composition and uses thereof | |
| US20240009261A1 (en) | Prebiotic compositions and method for weight loss by using the same | |
| CN115299610B (en) | Intestinal probiotics composition and application thereof | |
| CN117106679B (en) | Probiotic agent for relieving insulin resistance and application thereof | |
| KR102264188B1 (en) | Lactobacillus sakei MBEL1397 (KCTC14037BP) from danggui kimchi and composition with hypoglycemic effects thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |